Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 1;35(6):671-679.
doi: 10.1097/MOP.0000000000001279. Epub 2023 Jul 31.

Recent advances in immunomodulators for atopic dermatitis

Hyun J Yim  1 , Tiffany Jean  2 , Peck Y Ong  3   4
Affiliations
Review

Recent advances in immunomodulators for atopic dermatitis

Hyun J Yim et al. Curr Opin Pediatr. .

Abstract

Purpose of review: Conventional treatments of atopic dermatitis have been inadequate, especially in patients with moderate-to-severe disease.

Recent findings: In the past 5 years, four immunomodulators have been approved for the treatment of atopic dermatitis in children. These include dupilumab, ruxolitinib, upadacitinib, and abrocitinib. The review summarizes the pivotal phase 3 trials of these medications.

Summary: The newer immunomodulators have transformed the treatment of atopic dermatitis, particularly in patients with moderate-to-severe disease. Dupilumab targets IL-4 and IL-13, which are the main causes of allergic inflammation, resulting in great efficacy and few side effects. Upadacitinib and abrocitinib are alternative systemic medications for adolescents who have failed or are unable to tolerate dupilumab. Ruxolitinib cream is the latest addition to the current topical therapy. It is indicated for children 12 years and older with mild-to-moderate atopic dermatitis. Further studies are needed to confirm its safety and efficacy for younger children and for patients with more severe disease.

PubMed Disclaimer

References

    1. Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 2021; 126:417.e2–428.e2.
    1. Lloyd-Lavery A, Solman L, Grindlay DJC, et al. What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: epidemiology, aetiology and risk factors. Clin Exp Dermatol 2019; 44:370–375.
    1. Capozza K, Gadd H, Kelley K, et al. Insights from caregivers on the impact of pediatric atopic dermatitis on families: ‘i’m tired, overwhelmed, and feel like i’m failing as a mother’. Dermatitis 2020; 31:223–227.
    1. Ständer S. Atopic dermatitis. N Engl J Med 2021; 384:1136–1143.
    1. Ong PY. Atopic dermatitis: is innate or adaptive immunity in control? A clinical perspective. Front Immunol 2022; 13:943640.